MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.03 -0.96

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.99

Max

1.04

Schlüsselkennzahlen
By Trading Economics
Einkommen	-103K -6.6M
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+253.77% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.9M 68M
Vorheriger Eröffnungskurs	1.99
Vorheriger Schlusskurs	1.03

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. Apr. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. Apr. 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. Apr. 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. Apr. 2026, 20:57 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Apr. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. Apr. 2026, 20:25 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Apr. 2026, 19:30 UTC

Wichtige Nachrichtenereignisse

How Digital Currencies Have Helped Iran -- WSJ

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

253.77% Vorteil

12-Monats-Prognose

Durchschnitt 3.75 USD 253.77%

Hoch 4 USD

Tief 3.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.